Intelence

Etravirine, the active ingredient in Intelence, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is employed in the management of HIV‑1 infection, typically as part of combination antiretroviral therapy for adults and adolescents.

GNH USA supplies Intelence as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution.

Etravirine is indicated for HIV‑1 infection and is used as part of combination antiretroviral regimens.

HIV‑1 infection (treatment‑naïve patients): contributes to viral load reduction when combined with other antiretrovirals. HIV‑1 infection (treatment‑experienced patients with NNRTI resistance): offers an alternative option to achieve viral suppression. HIV‑1 infection (in combination with a protease inhibitor): enhances regimen potency in patients requiring intensified therapy.

Etravirine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Rash: skin erythema that may be pruritic. - Headache: transient cephalic pain. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe mucocutaneous reaction requiring immediate discontinuation. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Hypersensitivity reactions: including angioedema and anaphylaxis.

When prescribing Etravirine, clinicians should consider several precautionary measures.

Assess hepatic function: evaluate liver enzymes before initiation. Monitor for rash: discontinue if severe skin reactions develop. Check drug interactions: review concomitant medications for CYP3A4 inducers. Pregnancy and breastfeeding: weigh benefits against potential risks. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Etravirine interacts with several agents that can alter its plasma concentrations or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce Etravirine levels. - Potent CYP2C9 inhibitors (e.g., fluconazole): may increase exposure, risk of toxicity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours. - Protease inhibitors boosted with ritonavir: can increase Etravirine concentrations; monitor for adverse effects. - Other NNRTIs (e.g., efavirenz): may have additive toxicity; adjust regimen accordingly.